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The present review discusses intracellular signaling moieties specific to membrane
lipid rafts (MLRs) and the scaffolding proteins caveolin and introduces current data
promoting their potential role in the treatment of pathologies of the heart and brain.
MLRs are discreet microdomains of the plasma membrane enriched in gylcosphingolipids
and cholesterol that concentrate and localize signaling molecules. Caveolin proteins are
necessary for the formation of MLRs, and are responsible for coordinating signaling events
by scaffolding and enriching numerous signaling moieties in close proximity. Specifically in
the heart and brain, caveolins are necessary for the cytoprotective phenomenon termed
ischemic and anesthetic preconditioning. Targeted overexpression of caveolin in the heart
and brain leads to induction of multiple pro-survival and pro-growth signaling pathways;
thus, caveolins represent a potential novel therapeutic target for cardiac and neurological
pathologies.
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INTRODUCTION
Cardiac (i.e., ischemic heart disease, cardiomyopathy, congestive
heart failure) and neuronal (i.e., stroke, traumatic brain injury,
neurodegenerative disorders) diseases together represent a major-
ity of mortalities (Hoyert, 2012) and sources of disability (Soni,
2011) in the United States and the developed and developing
world. In survivors, these diseases are collectively associated with
a high rate of rehabilitation and institutionalization, which trans-
lates to a significant cost and resource burden on the healthcare
system (Soni, 2011). To date, clinical trials investigating pharma-
cologic therapies targeted at pro-survival pathways in the heart
and brain have been largely ineffective in enhancing recovery and
improving clinical outcome (Marler, 2007; Rose et al., 2010). This
may be due to a limited ability to regulate pro-survival signal-
ing that can occur in these organ systems following injury (Hicks
et al., 1998; Biegon et al., 2004; Atkins et al., 2007, 2009; Rose
et al., 2010). This review will highlight recent studies demonstrat-
ing that targeted augmentation of the subcellular microdomains
that coordinate the trafficking and localization of signaling events
restores multiple pro-survival and pro-growth signaling pathways
specifically in the heart and brain, which may provide a new ther-
apeutic avenue for treating a number of disease states affecting
these organ systems.
MEMBRANE LIPID RAFTS, CAVEOLAE, AND CAVEOLINS
Membrane lipid rafts (MLRs) are discreet microdomains of the
cell membrane that concentrate and localize signaling molecules
by providing a stable platform for protein anchoring. Stability
of protein anchoring is afforded by the lipid composition of
MLRs, which are rich in sphingomyelin, glycosphingolipids, and
cholesterol. By promoting a favorable binding environment for
cell signaling receptors and their downstream effectors, MLRs
promote a variety of physiological functions such as cell surface
signaling (Lisanti et al., 1994; Ostrom et al., 2001; Steinberg
and Brunton, 2001; Ostrom, 2002; Williams and Lisanti, 2004),
endocytosis (Anderson, 1993), calcium homeostasis (Fujimoto
et al., 1992; Fujimoto, 1993; Scriven et al., 2002) and intracel-
lular cholesterol transport (Murata et al., 1995; Smart et al.,
1996). Caveolae (Figure 1A), morphologic invaginations of the
cell surface, are subsets of MLRs containing sphingolipids and
cholesterol (Figure 1B) that were first observed in 1953 by Palade
(1953), but their role in cell-surface signaling has only been
realized in the past two decades. By regulating the intracellu-
lar trafficking and delivery of cholesterol to the cell membrane,
caveolar formation and stabilization is dependent on the key
structural protein, caveolin (Smart et al., 1999).
Caveolins (Figure 1C) are a family of proteins approximately
17–24 kDa in size that exist in three isoforms (Cav-1, -2, and -3),
all containing an invariant hydrophobic central domain that pro-
motes insertion in lipid bilayers in a hairpin loop manner, with
both the COOH and NH2 termini facing the cytoplasm (Dupree
et al., 1993; Dietzen et al., 1995; Monier et al., 1995; Tang et al.,
1996). Initial gene knockout (KO) studies provided evidence
that Cav-1 is essential for formation of caveolae in endothelial
cells, fibroblasts, and pneumocytes (Razani et al., 2001), whereas
Cav-2 plays an unclear but likely supportive role by forming
hetero-oligomers with Cav-1 (Monier et al., 1995; Razani et al.,
2001). Cav-3 KO mice are viable but subject to skeletal and
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FIGURE 1 | Caveolae are invaginations of the cell membrane readily
visualized via electron microscopy (A), which play a critical role in
pro-survival and pro-growth signaling. The formation and stabilization
of caveolae depend on the presence of cholesterol and the structural protein
caveolin, and serve to spatially localize signaling receptors (B), including
receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs).
Caveolin monomers (C), contains a palmitic acid anchor that serves to
stabilize the protein within the cell membrane, and a scaffolding domain,
which is the binding site for many pro-survival and pro-growth molecules.
(Definitions: EGFR, epidermal growth factor receptor; IGFR, insulin growth
factor receptor; PDGFR, platelet derived growth factor receptor; VEGFR,
vascular endothelial growth factor receptor; AC, adenylyl cyclase; PKA,
protein kinase A; PKC, protein kinase C; eNOS, endothelial nitric oxide
synthase; SFK, Src family kinases; MAPK, mitogen activated protein kinases).
cardiac myopathies (Hagiwara et al., 2000; Galbiati et al., 2001),
belying a critical role for Cav-3 in muscle (Tang et al., 1996;
Galbiati et al., 1998). However, all three caveolin isoforms have
been subsequently demonstrated in the central nervous system
(CNS) (Zschocke et al., 2002; Shin et al., 2005), suggesting a
greater degree of tissue ubiquity for Cav-3, despite early indi-
cations of specificity to muscle. Similarly, Cav-1 expression has
subsequently been demonstrated in both atrial (Volonte et al.,
2008) and ventricular myocytes (Cho et al., 2010). Caveolins are
also present in non-caveolar rafts, which exist as planar, tran-
sient membrane microdomains, where they are complexed with
glycophosphatidylinositol-anchored signaling proteins (Boscher
and Nabi, 2012), implying a spatial role in cell-surface and intra-
cellular signaling cascades. In fact all three caveolin isoforms con-
tain a conserved “caveolin scaffolding domain” (CSD, Figure 1C),
which functions as the physical binding site for a number of
signaling molecules.
CAVEOLINS COORDINATE MULTIPLE SIGNALING
PATHWAYS IN THE HEART
A number of signaling molecules localize to the MLR by aggre-
gating with the CSD on the C-terminal end of the caveolin pro-
tein (Figure 1C). G-protein coupled receptors (GPCRs) comprise
a large superfamily of transmembrane signaling receptors that
transduce extracellular molecules (e.g., endothelin, bradykinin,
serotonin, angiotensin-1, opioid, adenosine, and adrenergic) to
intracellular signals. It has been proposed that compartmentaliza-
tion of these receptors and other proteins in plasma membrane
microdomains may promote and regulate intracellular signaling
(Ostrom, 2002; Ostrom et al., 2002; Insel et al., 2005). Evidence
to support the interaction between GPCRs within MLRs came
from observations that the β2 adrenergic receptor localized to
lipid-rich buoyant fractions and within caveolae (Ostrom et al.,
2000; Rybin et al., 2000). Compartmentalization of signaling was
further suggested by experiments demonstrating that the inac-
tive Gα subunit may concentrate in caveolae and associate with
the CSD (Oh and Schnitzer, 2001), while activation of the sub-
unit causes Gα to dissociate and remain separate from caveolae
(Li et al., 1995). Moreover, endocytosis of ligand-bound GPCRs
occurs via a caveolae-dependent mechanism, which in turn ini-
tiates or terminates signaling (Escriche et al., 2003; Rapacciuolo
et al., 2003).
Endothelial nitric oxide synthase (eNOS) is involved in the
control of many important functions, such as angiogenesis,
vasorelaxation, and permeability. Mice deficient in Cav-1 display
increased nitric oxide (NO) production from increased eNOS
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activity (Razani et al., 2001) with resultant increased vascular
permeability in mouse lung endothelium (El-Yazbi et al., 2006),
both of which are reversed by injection of a truncated Cav-1 pep-
tide containing the CSD. Inhibition of eNOS by caveolin occurs
within the systemic vascular endothelium, whereby eNOS activ-
ity does not respond to regulatory signals, NO levels remain
increased, and basal cGMP levels remain elevated in rings of
aorta from Cav-1 deficient mice (Drab et al., 2001; Razani et al.,
2001). A role for Cav-1 as a direct negative regulator of eNOS
has been demonstrated whereby application of peptide contain-
ing the caveolin CSD in vivo resulted in selective inhibition of
NO (Bucci et al., 2000). However, an obligatory role for caveolin
on eNOS function has also been demonstrated, whereby deple-
tion of cholesterol resulted in disruption of agonist-stimulated
NO release in endothelial cells (Blair et al., 1999). While a role
for Cav-1 in endothelial NO production is evident, Cav-3 likely
also plays a critical role in NO signaling in skeletal and cardiac
tissue. Feron et al. (1996) first demonstrated a tissue-specific dif-
ferential pattern of caveolin/eNOS co-localization, whereby eNOS
was observed to complex with Cav-1 in endothelial cells, but
with Cav-3 in cardiac myocytes, while Segal et al. (1999) demon-
strated co-localization of Cav-3 and neuronal NOS (nNOS) in
skeletal muscle. Application of oligonucleotide coding for the
Cav-3 CSD to permeabilized cardiomyocytes specifically inhib-
ited a cholinergic-mediated decrease in myocyte chronotropy
and blunted elevations in cGMP, demonstrating modulation
of cardiac myocyte function via the interaction of Cav-1 and
eNOS (Feron et al., 1998). Global overexpression of Cav-3 was
subsequently shown to result in severe cardiomyopathy and
muscular dystrophy accompanied by downregulation of NOS
(Aravamudan et al., 2003). Modulation of cardiac and skeletal
muscle angiogenesis and vasoreactivity by the interaction of Cav-
3 and NOS may in part explain the phenotype of Cav-3 deficient
mice, which also includes both skeletal and cardiac myopathies
(Galbiati et al., 2001).
Another fundamental regulator of cell growth and dif-
ferentiation is protein phosphorylation via intracellular
kinases, downstream effectors of cell surface receptor bind-
ing. Phosphatidylinositol 3-kinase (PI3K) can be activated by
GPCRs or tyrosine kinase receptors, and is intimately involved in
cell growth and survival through activation of the anti-apoptotic
Akt pathway. In cultured skeletal myocytes, disruption of MLR’s
impairs cell survival via inhibition of PI3K/Akt (Smythe and
Rando, 2006). Furthermore, PI3K regulates insulin signaling,
whereby caveolin depletion alters insulin resistance in skeletal
muscle and adipose tissue (Cohen et al., 2003). Mitogen-
activated protein kinases (MAPK) represent another class of
protein kinases that regulate cell proliferation (Rose et al.,
2010). Increased MAPK activity downregulates Cav-1 mRNA
and protein levels, and overexpression of Cav-1 inhibits the
MAPK signaling pathways, an inhibition that is dependent on
the CSD (Engelman et al., 1998). Finally, tyrosine kinases are
thought to localize to MLRs and to interact with Cav-1 (Li et al.,
1996). Phosphorylation of Cav-1 occurs via the non-receptor
tyrosine kinase Src (Volonte et al., 2001), which can induce
muscle degeneration and inflammatory gene expression if Cav-1
expression and localization is disrupted (Smythe and Rando,
2006), but which has been implicated in myocardial protection
from ischemia/reperfusion (IR) injury (Patel et al., 2007).
Moreover, vascular endothelial growth factor receptor has been
reported to interact with Cav-1, and initiation of angiogenesis via
tyrosine kinase activation is dependent on the presence of Cav-1,
underlying a significant role for caveolin in the regulation of cell
growth and survival (Feng et al., 1999; Labrecque et al., 2003).
CAVEOLIN-3 REGULATES CARDIAC HYPERTROPHY
Stress on the heart produces pathogenic cell growth, whereby
hemodynamic overload induces an initial hypertrophic response
modulated by several signaling pathways that affect gene expres-
sion, apoptosis, inflammation, and growth factor signaling but
which ultimately ends in ventricular dilation and failure (Rohini
et al., 2010). Genetic deletion of Cav-1 results in a progres-
sive biventricular cardiomyopathy, with sustained activation of
MAPK, Akt and eNOS, and diminished ATP content in the heart
(Cohen et al., 2003). A recent study by Cruz et al. (2012) suggested
that elevated pulmonary pressures in Cav-1 deficient mice con-
tributed to eNOS uncoupling, whereby chronic hypoxia lead to
right ventricular hypertrophy, while endothelial-specific upregu-
lation of Cav-1 ablated these changes. Given that the expression
of Cav-1 is required for caveolar formation in non-muscle cells,
and caveolin-3 drives caveolae formation in cardiac and skele-
tal muscle, a Cav-1/3 double KO mouse was generated by Park
et al. (2002) in order to investigate phenotypic cardiac changes
in mice completely lacking morphologic caveolae. Cav-1/3 dou-
ble KO mice displayed a severe cardiomyopathy, with a dramatic
increase in left ventricular (LV) wall thickness, decreased LV frac-
tional shortening, disorganized, and degenerated cardiomyocyte
ultrastructure, chronic interstitial fibrosis and inflammation, and
augmentation of ANP expression as compared with Cav-1-KO,
Cav-3 KO, and wild-type mice (Park et al., 2002). While genetic
deletion of caveolin results in hypertrophy, global overexpression
of Cav-3 also results in a cardiomyopathic phenotype charac-
terized by degeneration and fibrosis (Aravamudan et al., 2003),
and as well as dystrophic skeletal muscle phenotype (Galbiati
et al., 2000). In contrast, Koga et al. (2003) demonstrated that
adenovirus-mediated overexpression of Cav-3 in isolated car-
diomyocytes provided protection from phenylephrine-induced
hypertrophy, suggesting that modulation of Cav-3 specifically in
cardiac myocytes may provide cardioprotection against dynamic
overload. Additionally, natriuretic peptides that can modulate
cardiac hypertrophy by regulating the adaptive response of the
heart to hemodynamic overload via diuretic, natriuretic and
vasodilatory action, are associated with caveolae and Cav-3
(Newman et al., 1991; Doyle et al., 1997). Subsequently, we
demonstrated that adenovirus-mediated overexpression of Cav-3
in cardiomyocytes augments natriuretic peptide expression and
Akt phosphorylation, which was blocked by PI3K inhibition and
caveolar disruption (Horikawa et al., 2011). Given the poten-
tial for Cav-3 to modulate cardiac hypertrophy, we next tested
whether targeting Cav-3 specifically to cardiac myocytes in vivo
would alter natriuretic peptide and Akt signaling and attenu-
ate the development of cardiac hypertrophy induced by hemo-
dynamic overload. We developed a cardiac-targeted (α-myosin
heavy chain promoter) Cav-3 overexpression system that caused
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a greater than twofold increase in Cav-3 specifically in cardiac
myocytes and subjected the mice to transverse aortic constric-
tion (TAC) for 1month, to induce cardiac hypertrophy. Mice with
cardiac-specific overexpression of Cav-3 exhibited augmentation
of natriuretic peptide expression and nuclear Akt phosphoryla-
tion, resulting in reduced cardiac hypertrophy following TAC,
with improved cardiac function and increased survival suggesting
a potential therapeutic role for Cav-3 in heart failure (Horikawa
et al., 2011).
CAVEOLIN-3 REGULATES CARDIAC ION CHANNELS IN
THE HEART
In addition to potential therapeuticmodalities targeting themito-
genic functions of caveolin, recent evidence suggests that Cav-3
expression is a critical element in modulation of membrane
potential via direct interaction with ion channels (O’Connell
et al., 2004; Balijepalli et al., 2006; Maguy et al., 2006; Balijepalli
and Kamp, 2008; Balse et al., 2012). In the cardiac myocyte, it
is established that one mechanism for Ca2+ influx occurs via
opening of voltage-gated Na+ channels which initiates depo-
larization through the cardiac sarcolemma, inducing activa-
tion of voltage-gated L-type Ca2+ channels (LCC), resulting
in Ca2+ influx into the cytosol and subsequent contraction.
However, current evidence suggest a more complicated sys-
tem of basal oscillating “sparks” and “puffs” of cytosolic Ca2+
mediated by ligand-gated receptors (Cheng and Lederer, 2008)
and contraction-independent LCCs (Makarewich et al., 2012).
Dysregulated Ca2+-flux through LCC is thought to play a role in
the development of cardiac hypertrophy, and early evidence sug-
gests flux through LCC in Cav-3 rich microdoamins as a locus for
this pathologic growth via the calcineurin-nuclear factor of acti-
vated T-cell signaling cascade (Makarewich et al., 2012). Cav-3
also is involved in the protein kinase A-dependent stimulation
of T-type Ca2+ channels, which are re-expressed in the adult
heart during hypertrophy and associated with cardiac dysfunc-
tion in heart failure (Markandeya et al., 2011). A recent study
by Guo et al. (2011) suggests that Cav-3 may modulate cardiac
hypertrophy and contractility via the GPCR subunit Gαq, which
is responsible for activation of phospholipase C-mediated Ca2+
flux in the cardiomyocyte. Moreover, Cav-3 appears necessary to
modulate adrenergic activation of protein kinase A and phospho-
rylation of phospholambam-independently of LCC in ventricular
myocytes (Macdougall et al., 2012). Caveolae appear to contribute
to regulation of excitation-contraction cycling through modu-
lation of both Ca2+ (Lohn et al., 2000; Bergdahl et al., 2003;
Kwiatek et al., 2006; Besse et al., 2011) and K+ flux (Martens
et al., 2001; Wang et al., 2005). Voltage-gated K+ channel localizes
to caveolae (Martens et al., 2001), while depletion of cholesterol
impairs maintenance of intracellular (K+), leading to destabiliza-
tion of membrane polarization (Fagan et al., 2000). Conduction
of depolarization throughout the heart also appears dependent
on caveolins, as Cav-3 KO animals display disorganization of the
T-tubule complex (Galbiati et al., 2001), and mutations in the
Cav-3 gene have been identified in patients with congenital long-
QT syndrome (Vatta et al., 2006). Modulation of caveolin levels
specifically in the heart therefore represents a potential mecha-
nism to restore the loss in contractility and/or rhythmicity that
occurs in pathogenic remodeling states such as congestive heart
failure.
CAVEOLIN-3 PROTECTS THE HEART FROM
ISCHEMIA/REPERFUSION INJURY
Caveolins have been shown to play a fundamental role in the
phenomenon of myocardial preconditioning, whereby an initial
priming stimulus confers cytoprotection to a subsequent bout
of IR. Historically, the first preconditioning stimulus described
in 1986 by Murry et al. (1986) was a short period of sub-lethal
ischemia which they termed ischemic preconditioning (IPC).
Subsequently both opioids (Schultz et al., 1997) and volatile anes-
thetic agents (Cason et al., 1997; Kersten et al., 1997), as well as
other pharmacologic agents that activate GPCRs, were shown to
confer a similar protective advantage. Preconditioning occurs in
a biphasic pattern: an early phase, which occurs within minutes
of the conditioning stimulus via post-translational modification
of pre-existing proteins, and lasts 1–2 h, and a delayed phase
occurring 12–24 h afterwards mediated by de novo synthesis of
pro-survival signaling components (Tonkovic-Capin et al., 2002).
Many of the signaling mediators involved in cardiac protec-
tion including the Gα subunit of heterotrimeric G-proteins, Src
kinases, PI3K, eNOS, MAPK, and the end-effector of IPC/APC,
the KATP channel, are known to localize to MLRs (Krajewska
and Maslowska, 2004). An early observation made by our labora-
tory was that IPC and APC induce alterations in the sarcolemmal
membrane ultrastructure of the myocyte, increasing the num-
ber of caveolae (Patel et al., 2006, 2007), and that the intrinsic
ability of rat cardiomyocytes to undergo opiod-induced precon-
ditioning depended on the presence of caveolae and localization
of the δ-opiod receptor with Cav-3 (Patel et al., 2006). In fol-
lowup studies, we utilized both in vitro and in vivo models to
demonstrate that early-phase APC operated via a Src-dependent
manner, whereby depletion of caveolae, deficiency of Cav-1 or
inhibition of Src resulted in abolishment of the cytoprotective
effects of the early-phase of isoflurane-induced preconditioning
(Patel et al., 2007). Additionally, we observed a decreased num-
ber of myocardial caveolae in Cav-3 deficient mice, and that such
mice cannot be “preconditioned” by IPC or APC (Horikawa et al.,
2008; Tsutsumi et al., 2008). Given these findings, we tested the
hypothesis that cardiac-specific overexpression of Cav-3 would
increase caveolae, and induce an innate level of cardiac protec-
tion similar to IPC. Adenovirus-mediated Cav-3 overexpression
in cardiomyocytes increased caveolar formation and induction
of IPC-mediated pro-survival kinases (Tsutsumi et al., 2008).
In vivo studies supported these findings: transgenic mice with
cardiac-specific (α-myosin heavy chain promoter) Cav-3 overex-
pression demonstrated increased myocardial caveolar formation,
augmentation of pro-survival kinases, and exhibited innate car-
dioprotection with improved cardiac function at a level similar to
that achieved through IPC (Tsutsumi et al., 2008).
While early-phase preconditioning appears to involve the
phosphorylation of preexisting proteins, delayed APC induces
gene and protein expression changes that ultimately lead to the
induction of various mediators, including induction of NOS
(Chiari et al., 2005) and synthesis of glucose-transporter 4
(Glut-4, Nishino et al., 2004). While a clear role for Cav-1 and
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Cav-3 exists in the induction of the early-phase of precondi-
tioing, we sought to investigate whether either caveolin isoform
contributed to the regulation of protein expression during the
delayed-phase of preconditioning. Using an in vivo approach,
we subjected both Cav-1 and Cav-3 deficient mice to isoflurane
exposure, followed by 24 h of recovery prior to IR, and observed
that both the formation of morphologic caveolae and induced
cardioprotection during delayed IPC was a Cav-3 dependent
event (Tsutsumi et al., 2010). The time-course of cardioprotection
appeared to coincide with translocation of Glut-4 to caveolae,
with co-localization of Cav-3/Glut-4 complexes within the LV.
Moreover, while early disruption of caveolae in cardiomyocytes
did not disrupt delayed cardioprotection, disruption of caveo-
lae following 24 h after isoflurane exposure (but just prior to IR)
did, implicating morphologic caveolae as necessary mediators in
the late-phase of APC (Tsutsumi et al., 2010). Collectively these
studies suggest that Cav-3 is both necessary and sufficient to pro-
mote the formation of caveolae and to induce both early and
delayed cardiac protection from IR injury. Interestingly, a recent
study by Waldenström et al. demonstrated that cardiomyocytes
secrete MLR-like microvescicle “exosomes” that contain Cav-3
(Waldenstrom et al., 2012), raising the intriguing possibility that
control of cell signaling may not be spatially restricted to a single
cell, and that caveolins may play a role in inter-cellular and possi-
bly inter-organ communication. Although our understanding of
the mechanisms by which caveolins and MLRs provide cardiac
protection remains incomplete, it appears that caveolin-induced
enhancement of pro-survival and pro-growth pathways offers a
promising avenue for clinical trials in the treatment of multiple
diseases of the heart.
CAVEOLIN-1 REGULATES NEURONAL SIGNALING
Although it is now recognized that all three caveolin isoforms
exist in neurons, a discreet absence of caveolae likely contributed
to the late recognition that caveolins are not only present within
neuronal cell membranes but also contribute to neuronal pro-
survival signaling (for review see Stern and Mermelstein (2010).
Caveolin-dependent signaling appears to be mediated by spa-
tial localization of relevant molecules, either through clustering
and sequestering, thereby exerting both positive and negative reg-
ulation of signaling (Galbiati et al., 1998). For example, while
Cav-1 knockdown impedes mobilization of intracellular Ca2+ by
serotonin 2A subtype-receptor (Bhatnagar et al., 2004), Cav-1
appears to internalize and attenuate the activity of the Gαs-
coupled dopamine receptor (Kong et al., 2007). Localization of
signaling is important in the neuron, as extra-synaptic activa-
tion may induce excitotoxicity (Figure 2), promoting cell death
(Hardingham and Bading, 2003). In neurons, Cav-1 co-localizes
with the synaptic-specific protein PSD-95 (Boeckers, 2006), and
with the pro-survival signaling receptors such as the NMDA
glutamate receptor subtype 2A, indicating spatial regulation of
neuronal signaling (Head et al., 2008). Targeting of caveolin
to the synapse suggests the pivotal role they are thought to
play in synaptic development of retinal ganglion cells (Mauch
et al., 2001) and at the neuromuscular junction (Willmann et al.,
2006). Cav-1 is expressed in multiple types of neurons, includ-
ing hippocampal and dorsal root ganglion neurons (Galbiati
FIGURE 2 | In the neuron, pro-survival signaling occurs via multiple
synaptic signaling receptors, including the NMDA glutamate receptor
(NMDAR), the neurotrophin-activated tyrosine kinase B receptor
(TrkR), and G-protein coupled receptors (GPCRs), which converge via
intracellular protein kinases (CaMKII, Src, Akt, cAMP) to phosphorylate
extracellular-signal regulated kinase 1/2 (ERK1/2), leading to
expression of pro-survival and pro-growth genes. These pro-survival
receptors localize and concentrate within the post-synaptic density (PSD),
a region enriched in caveolins, cholesterol and glycosphingolipids.
(Definitions: CaMKII, calcium/calmodulin-dependent protein kinase II;
cAMP, cyclic adenosine monophosphate).
et al., 1998; Peiro et al., 2000; Bu et al., 2003; Gaudreault et al.,
2004), and Cav-1 deficient mice exhibit neurological abnormal-
ities including, abnormal spinning, muscle weakness, reduced
activity, and gait abnormalities (Trushina et al., 2006). Additional
work demonstrates that Cav-1 KO mice exhibit an early aging
phenotype, which includes loss of synapses, enhanced astroglio-
sis and changes in the cerebrovasculature (Head et al., 2010).
Interestingly, Cohen et al. note in unpublished observations that
Cav-1 KO mice display an increased sensitivity to inhaled anes-
thetics (Cohen et al., 2003), resulting in profound bradycardia
given a standard level of anesthetic. Whether these observations
aremediated by a central or peripheralmechanism is unclear. One
intriguing phenomenon proposed by Lucchinetti et al. (2008)
considers the preferential partitioning of halogenated ethers to
amphiphilic interfaces [such as lipid rafts (Morgan et al., 2004)]
as a significant event in cell signaling, whereby exposure to
anesthetics may alter the interaction of specific protein-protein
and/or protein-lipid interactions, thereby resulting in remod-
eling of the signaling architecture within the cell. As noted
above, we have observed this in cardiomyocytes (Patel et al.,
2007), whereby exposure to isoflurane resulted in an increase in
morphological caveolae, supporting a mechanism where halo-
genated ethers alter the physiochemistry of the cell membrane.
However, given that neurons do not exhibit morphologic cave-
olae it remains unclear whether MLRs in fact play a significant
role in the anesthetic effects of halogenated ethers in the CNS.
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Currently this area has not been investigated and remains largely
unknown.
Similar to myocardium, caveolins in neurons coordinate
GPCRs, ion channels, and downstream kinase activation.
Pro-survival signaling in neurons occurs following activation
of a number of synaptic receptors, including GPCRs, the
neurotrophin-activated tyrosine kinase B (TrkB) receptor, and
the glutamate receptor, which share the common final path-
way of phosphorylation of the cAMP response element binding
protein (CREB), initiating transcription of pro-growth genes
(Figure 2). Cav-1 and MLRs can regulate estrogen GPCR sig-
naling (Mermelstein, 2009), whereas Cav-3 inhibition leads to
loss of the estrogen-mediated inhibition of L-type Ca2+ channel-
dependent CREB phosphorylation (Boulware et al., 2007). This
latter effect may lead to Ca2+ flux and potentially neuro-
muscular contraction, synaptic transmission or upregulation of
gene expression. Ionotropic receptor, TrkB-receptor, and GPCR-
mediated neurotransmission appear to be caveolin-dependent
(Head et al., 2008, 2011; Francesconi et al., 2009; Takayasu et al.,
2010). Positive regulation of 5-HT2AR, a subtype of GPCR, likely
occurs through facilitating binding between the receptor and
Gαq subunit (Bhatnagar et al., 2004). Similarly, the activation of
the NMDA receptor appears to be mediated by both Cav-1 and
Cav-3 via controlled coordination of the Gαq subunit, with sub-
sequent modulation of the pro-growth pathway ERK1/2 (Head
et al., 2008). For example, we demonstrated that loss of Cav-1
expression disrupts NMDA receptor signaling and attenuates pro-
survival Src and ERK1/2 phosphorylation in response to NMDA
or simulated ischemia (Head et al., 2008, 2011).
CAVEOLIN-1 PROTECTS NEURONS FROM ISCHEMIC
INJURY AND PROMOTES DENDRITIC GROWTH
Cerebral ischemia decreases the integrity of cell membranes and
thus may disrupt caveolin-associated signaling complexes. A neu-
roprotective role for Cav-1 was first demonstrated in Cav-1 KO
mice, which had a larger cerebral infarct size in response to
ischemia (Jasmin et al., 2007) that may have been due to alter-
ations in the permeability of the blood brain barrier (Gu et al.,
2012) secondary to Cav-1 related translocation of the tight-
junction protein claudin-5 (Liu et al., 2012). It was subsequently
demonstrated that intracerebral hemorrhage resulted in elevated
inflammatorymediators and a larger region of neuronal cell death
in Cav-1 KO mice (Chang et al., 2011). This may be due to the
complex role that signaling receptors are thought to play in the
developing brain (Li et al., 1998), whereby disruption of MLRs
results in multiple signaling deficiencies (Mauch et al., 2001;
Willmann et al., 2006). Our laboratories corroborated the essen-
tial role of Cav-1 in phosphorylation of Src and ERK1/2 and
IPC, by demonstrating that Cav-1 deficient neurons were unable
to undergo preconditioning, while return of Cav-1 restored the
capacity of the neuron to undergo the cytoprotective effect (Head
et al., 2008, 2011). In addition to greater sensitivity to ischemia,
mice deficient in Cav-1 have a CNS pathology similar to that
exhibited in neurodegenerative diseases, including altered glu-
tamate receptor signaling (Head et al., 2008; Francesconi et al.,
2009; Takayasu et al., 2010), and impaired cholinergic function
(Trushina et al., 2006; Jasmin et al., 2007; Gioiosa et al., 2008).
A role for caveolin-associated neurodegenerative disorders
may be found in the lipid composition of the MLR (Parton, 1994),
in particular GM-gangliosides, which are concentrated within
MLRs and have been associated with autoimmune disorders such
as lupus and Guillain-Barré syndrome (Bansal et al., 1994), in
addition to being implicated in the development of dementia
(Bansal et al., 1994). Interestingly, in post-mortem samples of
human hippocampus and cortex in patients with Alzheimer’s dis-
ease, cytospatial distribution of Cav-1 and the voltage-dependent
anion channel (VDAC) is increased (Ramirez et al., 2009). Since
the VDAC is thought to play a role in Alzheimer’s-associated
amyloid-β neurotoxicity (Ferrer, 2009), caveolins may play a
prominent role in the modulation of amyloid precursor pro-
tein processing, and thus the development and progression of
Alzheimer’s disease. For example, functional Cav-1 plays a role
in HIV-related accumulation of amyloid-β (Andras et al., 2012),
while Cav-1 deficient mice develop a pathological phenotype sim-
ilar to that of Alzheimer’s disease (Head et al., 2010). Aging
increases the likelihood of dementia and Alzheimer’s disease, and
localization of synaptic signaling components in neuronal MLRs
is reduced in brains from aged WT and young Cav-1 KO mice
(Head et al., 2010). Clearly, more research is needed on the reg-
ulatory role of caveolins/MLR on the activity of key secretases
involved in amyloid processing.
Functional recovery from brain injury (i.e., stroke or trauma)
and neurodegeneration is limited by a reduction in pro-survival
and pro-growth signaling (Atkins et al., 2007), which increases
neuronal loss, impairs brain repair, and increases functional
deficits. This may explain why exogenous pharmacologic inter-
ventions targeting pro-survival pathways individually have
been relatively ineffective. We have demonstrated that loss of
Cav-1 decreases expression of MLRs, neurotransmitter and
neurotrophin receptors, impairs neurotransmitter transduction,
and attenuates pro-survival signaling (Head et al., 2008, 2011). A
recent study (Lim et al., 2011), demonstrating that administration
of exogenous gangliosides, a component of the MLR, resulted in
augmentation of neurotrophic signaling in rat hippocampal and
human neuronal cell lines, providing evidence that restoration of
signaling may promote neuronal growth and improve functional
outcome. However non-specific augmentation in pro-growth
signaling may promote neoplastic processes, as there is evidence
that the development of glioma is associated with increased Cav-1
production in astrocytes (Parat and Riggins, 2012). To this end,
our laboratory utilized the neuron-specific promoter synapsin
to overexpress Cav-1, which led to enhanced expression of
MLRs, neurotransmitter and neurotrophin receptors specifically
in neurons (Head et al., 2011). This resulted in an increase in
pro-survival and pro-growth signaling molecules, translating
to dendritic growth and arborization, even in the presence of
inhibitory mediators. These promising results demonstrate that
restoration of pro-survival and pro-growth signaling may be both
necessary and sufficient to provide a therapeutic benefit in the
functional recovery from brain injury and neurodegeneration.
CONCLUSIONS
In the years following George Palade’s first observations of cave-
olae nearly 60 years ago, diffusion-based fluid-mosaic models of
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the cell surface membrane (Singer and Nicolson, 1972) could
not account for the speed and fidelity with which intracellular
signaling occurs. It is clear now that the complexity of orches-
trating multiple sub-cellular signaling events is accomplished by
the focal concentration of signaling moieties within the MLR.
This highly organized structure is dependent on caveolins, which
facilitate and coordinate the spatial and temporal organization
necessary to achieve multiple, simultaneous signaling activities.
However, the model that caveolin is the only structural protein
necessary for the formation of caveolae is becoming more com-
plex with the description of the “cavin” family of proteins and
other membrane proteins such as pacsin-2/syndapin-2, which are
now known to play a key role in the formation and function of
caveolae (Hansen and Nichols, 2010; Briand et al., 2011). Future
work will need to focus on how the interaction of caveolins, cavins
and other membrane structural proteins in and out of caveo-
lar microdomains influences the potential pro-survival role of
caveolins in the heart and brain.
By augmenting the expression of caveolin in the heart and
brain, multiple pro-survival and pro-growth pathways are simul-
taneously upregulated, which is sufficient, and likely necessary,
for inducing cardiac and neuroprotection. It remains to be
resolved how control of caveolin expression can be harnessed
in a clinical fashion to produce a beneficial therapeutic out-
come. In addition to developing a gene delivery vehicle that is
safe and efficacious in patients, post-transcriptional regulators
such as RNAses and micro-RNAs may be able to be engineered
to affect the gene expression machinery to augment potential
protein therapies. Micro-RNAs (“miRs”) are small non-coding
RNAs that serve to regulate post-transcriptional gene expression
by binding to mRNA and repressing translation or degrading
mRNA entirely. They are highly abundant in the brain and have
been known to localize to subcellular regions such as dendritic
spines and can affect spine structure/morphology, function, and
synaptic plasticity (Gao et al., 2010; Saugstad, 2010). Although
cell-specific genetic manipulation in vivo via viral vector delivery
(e.g., adenoviral, adeno-associated viruses) has great therapeu-
tic/translational potential, the use of small molecules to induce
cell specific enhancement in mRNA translation will allow us to
achieve alterations in protein expression-independent of viral
vectors. An example is the use of complementary inhibitors of
miRs, termed “antagomirs.” In regard to caveolin-specific miR
inhibition, one group showed that the use of antagomirs to block
Cav-1 associated miRs (miRs 103/107) and subsequently enhance
Cav-1 protein expression reversed a type II diabetic phenotype
(Trajkovski et al., 2011). Because caveolins afford robust pro-
tection against ischemic injury in both cardiac and neuronal
tissue, identifying caveolin miRs specifically in the heart, brain,
and spinal cord may allow us to design effective antagomirs
with significant pharmaceutical implications. Given the potential
of caveolin therapy to augment pro-growth signaling pathways,
technologies to control the temporal expression of caveolins may
be necessary as an “on–off” switch to prevent neoplasia. Although
many aspects of harnessing the spatial and temporal regulation of
cell signaling by caveolins remain to be determined, the studies
described above represent a promising new therapeutic approach
in which targeting cell survival signaling via caveolin expres-
sion may prove to not only augment existing pharmacologic
modalities aimed at individual pro-survival pathways, but may
alone be sufficient to promote cell survival and growth in a
number of diseases of the heart and brain.
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